ClinicalTrialsFinder

Biomarker-selected CLDN18.2-positive and/or HER2-positive Disease Clinical Trials in Shenzhen, Guangdong

1 recruitingShenzhen, Guangdong, China

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

Dual-Target CLDN18.2/HER2 CAR-NK Cells for Advanced Esophageal Adenocarcinoma

Recurrent or Metastatic Esophageal AdenocarcinomaBiomarker-selected CLDN18.2-positive and/or HER2-positive Disease
Beijing Biotech36 enrolled1 locationNCT07622940